Citicoline dosage

Citicoline (CDP-choline) is sold in the United States as a dietary supplement, not an FDA-approved drug, and CDP-choline and citicoline are the same compound. If you are researching citicoline dosage, the most honest answer is that there is no officially established dose. What exists is a range of doses used in clinical trials, and those trials cover very different conditions, with very different results.

In trials, citicoline has generally been well tolerated at 250 to 2,000 mg per day, with mild side effects such as stomach upset, headache, and insomnia. But "studied at a dose" is not the same as "proven to work at that dose." The two largest trials, in acute stroke and traumatic brain injury, used substantial doses and found no benefit over placebo. Smaller trials that reported positive findings used lower doses, were often industry funded, and were not always high quality.

This article reports only the doses used in published studies. It is not a personal dosing protocol. Before taking citicoline at any dose, talk to your doctor, especially if you take other medications. For a broader overview, see our citicoline safety hub and our guide to citicoline side effects.

Evidence at a glance

What "dosage" means in the citicoline research

When people search for citicoline dosage, they usually want a number to take each day. The research does not provide that kind of number. It provides doses that were tested in specific groups of people for specific conditions, under medical supervision.

The studied range is wide: 250 mg per day at the low end, up to 2,000 mg per day at the high end. Within that range, results were inconsistent. The biggest and best-run trials, which used higher doses, found no benefit. The smaller positive trials used lower doses, which tells you that dose size alone does not explain whether a trial "worked." Study quality, condition, and funding source matter more.

Cognizin is a branded form of citicoline, and it funded the attention studies described below. The compound is the same either way: citicoline and CDP-choline are identical.

Doses in the large negative trials

The two most important trials for anyone thinking about citicoline dosage are negative ones, and it would be misleading to leave them out of a dosage discussion.

In acute stroke, the ICTUS trial (Dávalos, Lancet 2012) enrolled about 2,300 people and found no improvement in 90-day recovery versus placebo. Earlier stroke meta-analyses had suggested benefit at studied doses, but ICTUS, the largest and most rigorous test, did not confirm that benefit. Whatever dose was used, it did not produce recovery better than placebo in this large trial.

In traumatic brain injury, the COBRIT trial (Zafonte, JAMA 2012) tested citicoline and found no improvement in functional or cognitive outcomes versus placebo. Again, a carefully designed trial at a real therapeutic dose failed to show a benefit.

The lesson for dosage questions is simple: a dose that is well tolerated and used in a major trial can still be a dose that does nothing measurable for the condition being treated.

Doses in the smaller positive studies

The studies that reported benefits used doses at the lower end of the range.

For adult attention, McGlade 2012 studied women given 250 mg or 500 mg per day of a Cognizin-branded product and found better attention-test scores. A separate McGlade study in adolescent males found gains in attention and psychomotor speed. Both were small trials, and both were funded by the maker of Cognizin, which is a reason for caution when interpreting the results.

For chronic cerebrovascular cognitive decline, a Cochrane review by Fioravanti and Yanagi found modest short-term benefit on memory and behaviour at the doses studied, but the underlying trials were short and low quality. An observational study in mild vascular cognitive impairment, IDEALE (Cotroneo), reported stable scores in a treated group versus decline in an untreated group, but observational designs cannot prove the treatment caused the difference.

On ADHD, there are no adequate trials at any dose. There is no good evidence citicoline treats ADHD, so there is no studied ADHD dose to report.

Safety, tolerability, and drug interactions

Across trials, citicoline was generally well tolerated at 250 to 2,000 mg per day. Reported side effects were mild: gastrointestinal upset, headache, and insomnia. Pregnancy and breastfeeding data are lacking, so no safe dose has been established for those groups.

One interaction deserves attention. Citicoline may enhance the effects of levodopa. People with Parkinson's disease should involve their neurologist before taking citicoline at any dose, because their levodopa regimen may need adjustment.

Because citicoline is a supplement in the US, product quality and actual content per capsule can vary between brands. That is another reason the label number is only a starting point for a conversation with your doctor, not a recommendation.

Expert insight

When patients ask me about citicoline dosage, I start by separating two questions: what dose was studied, and what dose is right for them. The studied range is 250 to 2,000 mg per day, and within that range citicoline was generally well tolerated, with mild stomach upset, headache, and insomnia as the main complaints. But I am direct about the evidence: the two largest trials, ICTUS in stroke and COBRIT in brain injury, found no benefit over placebo at real therapeutic doses. The positive findings come from smaller trials, some of them industry funded, at doses of 250 to 500 mg per day, and from a Cochrane review built on short, low-quality studies. Mechanistically, citicoline may support membrane phospholipid synthesis, but neuroprotection remains preclinical only, so we cannot reason our way to a dose from the mechanism. My consistent advice is to bring the specific product and dose you are considering to your own doctor, and to involve your neurologist if you take levodopa.

Questions readers ask

What is the standard citicoline dosage?

There is no officially established standard dose. Citicoline is a dietary supplement in the US, not an FDA-approved drug. Trials have used 250 to 2,000 mg per day, but a studied dose is not a recommended dose.

What doses were used in the attention studies?

McGlade 2012 gave adult women 250 mg or 500 mg per day and found better attention-test scores. A separate study in adolescent males found attention and psychomotor speed gains. Both were small and funded by Cognizin, the brand manufacturer.

Is a higher citicoline dose more effective?

The evidence does not support that idea. The largest trials, ICTUS in stroke and COBRIT in traumatic brain injury, used substantial doses and found no benefit over placebo. The positive findings came from smaller studies at lower doses.

What is the maximum dose studied?

Trials have used up to 2,000 mg per day, and citicoline was generally well tolerated across the 250 to 2,000 mg range. That describes tolerability in studies, not a safe personal maximum. Talk to your doctor before using any dose.

Is citicoline safe during pregnancy or breastfeeding?

Pregnancy and breastfeeding data are lacking. No dose has been established as safe for these groups, so discuss it with your doctor before considering use.

Does citicoline interact with any medications?

It may enhance the effects of levodopa. People with Parkinson's disease should involve their neurologist before taking citicoline, at any dose.

Is there a studied citicoline dose for ADHD?

No. There are no adequate trials of citicoline for ADHD, and there is no good evidence it treats ADHD. No studied ADHD dose exists.

Are citicoline and CDP-choline dosed differently?

No. They are the same compound, and Cognizin is simply a brand of it. The label wording does not change what is inside.

For help preparing for that conversation, see our questions for your doctor and the rest of our dosage and safety coverage.

Sources

This article draws on: the ICTUS trial (Dávalos, Lancet 2012) in acute stroke; earlier stroke meta-analyses; the COBRIT trial (Zafonte, JAMA 2012) in traumatic brain injury; the Cochrane review by Fioravanti and Yanagi on chronic cerebrovascular cognitive decline; the IDEALE study (Cotroneo) in mild vascular cognitive impairment; small glaucoma adjunct trials from the Parisi and Rossetti groups; McGlade 2012 in adult women and the McGlade adolescent male study, both Cognizin-funded; and the safety and tolerability record across trials at 250 to 2,000 mg per day. PMIDs are not listed until each one is confirmed on PubMed.